StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
26
This year
1
Publishing Date
2024 - 01 - 04
1
2023 - 11 - 27
2
2023 - 07 - 17
1
2023 - 04 - 26
2
2023 - 03 - 29
1
2023 - 02 - 24
1
2022 - 12 - 21
2
2022 - 10 - 14
1
2022 - 09 - 30
1
2022 - 09 - 15
1
2022 - 09 - 12
1
2022 - 08 - 29
1
2022 - 07 - 14
3
2022 - 01 - 19
1
2021 - 12 - 13
1
2021 - 12 - 08
1
2021 - 09 - 29
1
2021 - 05 - 24
1
2021 - 05 - 12
1
2021 - 03 - 15
1
2021 - 01 - 26
1
Sector
Health technology
26
Tags
Alliances
1
Alzheimer’s
3
Antibody
1
Approval
1
Approved
3
Atopic dermatitis
1
Cancer
6
Casirivimab
1
Cell
1
Cell carcinoma
1
Children
6
Chmp
3
Clinical-trials-phase-i
1
Clinical-trials-phase-iii
2
Copd
2
Covid
2
Dermatitis
2
Diabetic
1
Disease
5
Dupixent
11
Europe
1
Evkeeza
1
Fda
2
Genetown
2
Hypercholesterolemia
1
Lancet
1
Libtayo
4
Lung
2
Macular
1
N/a
17
Nephropathy
1
News
1
Pharm-country
1
Phase 2
1
Phase 3
8
Positive
26
Potential
2
Report
2
Research
1
Results
10
Sanofi
1
Study
1
Submission
2
Therapy
1
Treatment
4
Trial
6
Trial results
1
Vaccine
1
Entities
Alnylam pharmaceuticals, inc.
4
Regeneron pharmaceuticals, inc.
26
Sanofi
24
Teva pharmaceutical industries ltd
10
Ultragenyx pharmaceutical inc.
1
Symbols
ABBV
32
ADIL
10
ALNY
19
ALPMF
16
ALPMY
16
AMGN
17
ANVS
10
AQST
18
ARVL
33
AUY
10
AZN
18
BBIO
16
BGNE
21
BIIB
13
BMY
33
BNTX
18
BYSI
11
CHRS
24
CLDX
10
CLSD
15
DARE
13
FNCTF
40
GILD
14
GSK
13
HOTH
14
IMMP
12
IMMX
11
INCY
17
IONS
21
IT
31
JNJ
55
LLY
34
LTUM
18
MDWD
11
MRK
21
MS
12
NDAQ
86
NVS
24
NVSEF
20
PDSB
11
PFE
46
PPRUF
13
PPRUY
13
PSN
14
RCKT
11
REGN
26
RGNX
17
SCYX
11
SGEN
13
SLS
11
SNY
114
SNYNF
90
SRNE
22
TAK
14
TAYD
17
TEVJF
14
TNXP
12
VIRX
14
VRTX
11
ZLAB
11
Exchanges
Nasdaq
26
Crawled Date
2024 - 01 - 04
1
2023 - 11 - 27
2
2023 - 07 - 17
1
2023 - 04 - 26
2
2023 - 03 - 29
1
2023 - 02 - 24
1
2022 - 12 - 21
2
2022 - 10 - 14
1
2022 - 09 - 30
1
2022 - 09 - 15
1
2022 - 09 - 12
1
2022 - 08 - 29
1
2022 - 07 - 14
3
2022 - 01 - 19
1
2021 - 12 - 13
1
2021 - 12 - 08
1
2021 - 09 - 29
1
2021 - 05 - 24
1
2021 - 05 - 12
1
2021 - 03 - 15
1
2021 - 01 - 26
1
Crawled Time
06:00
2
07:00
5
08:00
1
09:00
2
12:00
2
13:00
4
15:00
1
18:00
1
21:00
1
22:00
1
23:00
6
Source
www.biospace.com
9
www.globenewswire.com
9
www.prnewswire.com
8
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
positive
symbols :
Regn
save search
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Published:
2024-01-04
(Crawled : 13:00)
- globenewswire.com
RARE
|
News
F
|
$42.37
-2.33%
-2.38%
680K
|
Health Technology
|
-8.01%
|
O:
0.83%
H:
1.57%
C:
-2.61%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
-1.78%
|
O:
0.02%
H:
0.77%
C:
-0.61%
evkeeza
positive
hypercholesterolemia
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published:
2023-11-27
(Crawled : 07:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-2.62%
|
O:
-0.36%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-3.4%
|
O:
1.04%
H:
0.17%
C:
0.11%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
12.89%
|
O:
0.46%
H:
0.37%
C:
-0.49%
dupixent
fda
disease
approved
positive
copd
potential
submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published:
2023-11-27
(Crawled : 07:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-2.62%
|
O:
-0.36%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-3.4%
|
O:
1.04%
H:
0.17%
C:
0.11%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
12.89%
|
O:
0.46%
H:
0.37%
C:
-0.49%
dupixent
fda
disease
approved
positive
copd
potential
submission
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-07-17
(Crawled : 09:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-13.66%
|
O:
0.02%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
25.42%
|
O:
0.05%
H:
1.33%
C:
0.38%
ALNY
|
$144.315
-0.58%
-0.59%
700K
|
Health Technology
|
-26.35%
|
O:
5.53%
H:
5.23%
C:
-2.49%
disease
alzheimer’s
positive
results
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-04-26
(Crawled : 23:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-17.96%
|
O:
-1.46%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-20.82%
|
O:
0.53%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
14.14%
|
O:
-0.99%
H:
0.38%
C:
-0.48%
ALNY
|
$144.315
-0.58%
-0.59%
700K
|
Health Technology
|
-28.19%
|
O:
-0.76%
H:
0.33%
C:
-1.54%
disease
report
alzheimer’s
positive
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-04-26
(Crawled : 23:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-17.96%
|
O:
-1.46%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-20.82%
|
O:
0.53%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
14.14%
|
O:
-0.99%
H:
0.38%
C:
-0.48%
ALNY
|
$144.315
-0.58%
-0.59%
700K
|
Health Technology
|
-28.19%
|
O:
-0.76%
H:
0.33%
C:
-1.54%
disease
report
alzheimer’s
positive
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Published:
2023-03-29
(Crawled : 12:00)
- globenewswire.com
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-15.92%
|
O:
1.07%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
8.97%
|
O:
0.37%
H:
0.6%
C:
-1.28%
libtayo
lung
approved
positive
cancer
cell
treatment
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Published:
2023-02-24
(Crawled : 13:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-4.53%
|
O:
-2.11%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-4.23%
|
O:
0.72%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
18.63%
|
O:
-0.77%
H:
1.52%
C:
0.42%
libtayo
treatment
lung
chmp
positive
cancer
Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Published:
2022-12-21
(Crawled : 23:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-4.99%
|
O:
1.82%
H:
0.0%
C:
-2.17%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-5.73%
|
O:
-0.4%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
22.41%
|
O:
-0.01%
H:
0.06%
C:
-0.33%
dupixent
positive
results
Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
Published:
2022-12-21
(Crawled : 23:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-4.99%
|
O:
1.82%
H:
0.0%
C:
-2.17%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-5.73%
|
O:
-0.4%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
22.41%
|
O:
-0.01%
H:
0.06%
C:
-0.33%
dupixent
positive
results
Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
Published:
2022-10-14
(Crawled : 15:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
22.68%
|
O:
6.95%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
16.96%
|
O:
2.74%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
19.75%
|
O:
0.0%
H:
1.13%
C:
-2.19%
libtayo
chmp
approval
positive
cancer
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
Published:
2022-09-30
(Crawled : 22:00)
- prnewswire.com
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
macular
positive
results
diabetic
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Published:
2022-09-15
(Crawled : 23:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
16.59%
|
O:
0.74%
H:
0.91%
C:
-0.74%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
11.9%
|
O:
-0.52%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
27.67%
|
O:
0.62%
H:
1.12%
C:
0.01%
dupixent
children
lancet
dermatitis
positive
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
Published:
2022-09-12
(Crawled : 09:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
16.35%
|
O:
-0.78%
H:
0.58%
C:
0.58%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
11.87%
|
O:
1.6%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
24.42%
|
O:
-0.55%
H:
0.43%
C:
-1.33%
libtayo
positive
cell carcinoma
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published:
2022-08-29
(Crawled : 13:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
9.64%
|
O:
-1.08%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
51.16%
|
O:
-0.64%
H:
1.24%
C:
0.07%
ALNY
|
$144.315
-0.58%
-0.59%
700K
|
Health Technology
|
-31.18%
|
O:
-0.56%
H:
1.41%
C:
-0.34%
treatment
nephropathy
positive
study
phase 2
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Published:
2022-07-14
(Crawled : 12:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.51%
|
O:
-1.46%
H:
0.09%
C:
0.09%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-8.1%
|
O:
-1.27%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
49.69%
|
O:
-1.0%
H:
1.64%
C:
0.48%
dupixent
children
trial
positive
results
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial asses...
Published:
2022-07-14
(Crawled : 07:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.51%
|
O:
-1.46%
H:
0.09%
C:
0.09%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-8.1%
|
O:
-1.27%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
49.69%
|
O:
-1.0%
H:
1.64%
C:
0.48%
dupixent
children
trial
positive
results
sanofi
phase 3
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published:
2022-07-14
(Crawled : 06:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.51%
|
O:
-1.46%
H:
0.09%
C:
0.09%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-8.1%
|
O:
-1.27%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
49.69%
|
O:
-1.0%
H:
1.64%
C:
0.48%
dupixent
children
trial
positive
results
phase 3
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Published:
2022-01-19
(Crawled : 07:00)
- globenewswire.com
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-13.36%
|
O:
-1.41%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
48.74%
|
O:
1.84%
H:
1.79%
C:
0.18%
dupixent
trial
positive
phase 3
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published:
2021-12-13
(Crawled : 08:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-4.51%
|
O:
3.01%
H:
0.28%
C:
-2.39%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-6.75%
|
O:
-0.42%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
36.2%
|
O:
-1.54%
H:
0.0%
C:
0.0%
dupixent
atopic dermatitis
dermatitis
positive
children
phase 3
← Previous
1
2
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.